Sumitomo Pharma Co Ltd
TSE:4506
Sumitomo Pharma Co Ltd
Long-Term Debt
Sumitomo Pharma Co Ltd
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sumitomo Pharma Co Ltd
TSE:4506
|
Long-Term Debt
¥119.5B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
36%
|
CAGR 10-Years
4%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Long-Term Debt
¥4.7T
|
CAGR 3-Years
4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
19%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Long-Term Debt
¥100.9B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-7%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Long-Term Debt
¥160.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
22%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Long-Term Debt
¥4.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
38%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Long-Term Debt
¥564.9B
|
CAGR 3-Years
117%
|
CAGR 5-Years
34%
|
CAGR 10-Years
97%
|
|
Sumitomo Pharma Co Ltd
Glance View
In the bustling world of pharmaceuticals, Sumitomo Pharma Co. Ltd. stands as a testament to innovation and resilience. Emerging from its roots in Sumitomo Dainippon Pharma, this Japanese giant has been weaving a complex tapestry of cutting-edge medical advancements and strategic mergers for decades. At its core, Sumitomo Pharma is fueled by an unwavering commitment to research and development, driving its efforts in therapeutic areas such as psychiatry, neurology, and oncology. These focal points aren't mere business segments but vital lifelines that the company seeks to improve with its products. Their success heavily relies on their ability to translate research into actionable, marketable treatments; it's a dance between science and commerce, with the rhythm dictated by patient needs and market demands. Sumitomo Pharma's financial engine is powered not just by their innovative drug pipeline but also through savvy global partnerships and strategic acquisitions. By expanding its footprint across North America, Europe, and Asia, the company meticulously builds a global distribution network that ensures its products reach the hands of physicians and patients worldwide. This extensive reach allows Sumitomo Pharma to tap into diverse markets, fueling both sales and brand recognition. Moreover, through its alliances with biotech firms and academic institutions, the company enhances its research capabilities, fostering a cycle of innovation that feeds back into its financial growth. In essence, Sumitomo Pharma doesn't just participate in the pharmaceutical industry; it actively shapes it, both through its dedication to breakthrough therapies and its strategic navigation of complex global markets.
See Also
What is Sumitomo Pharma Co Ltd's Long-Term Debt?
Long-Term Debt
119.5B
JPY
Based on the financial report for Dec 31, 2024, Sumitomo Pharma Co Ltd's Long-Term Debt amounts to 119.5B JPY.
What is Sumitomo Pharma Co Ltd's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
4%
Over the last year, the Long-Term Debt growth was -35%. The average annual Long-Term Debt growth rates for Sumitomo Pharma Co Ltd have been -21% over the past three years , 36% over the past five years , and 4% over the past ten years .
You don't have any saved screeners yet